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Could there be a fine-tuning role for brain-derived
adipokines in the regulation of bodyweight and
prevention of obesity?
Russell E. Brown*
ABSTRACT: Obesity is one of the most prevalent medical conditions, often associated with several
negative stereotypes. Although it is true that weight gain occurs when food intake exceeds energy
expenditure, it is important to note that even a 1% mismatch between the two can lead to a substantial
weight gain after only a few years. Further, the body appears to balance energy metabolism via an
endogenous lipostatic loop in which adipose stores send hormonal signals (e.g. adipokines such as
leptin) to the hypothalamus in order to reduce appetite and increase energy expenditure. However, the
brain is also a novel site of expression of many of these adipokine genes. This led to the hypothesis that
hypothalamic-derived adipokines might also be involved in bodyweight regulation by exerting some
effect on the control of appetite or hypothalamic function. When RNA interference (RNAi) was used to
specifically silence adipokine gene expression in various in vitro models, this led to increases in cell
death, modification of the expression of key signaling genes (i.e. suppressor of cytokine signaling-3;
SOCS-3), and modulation of the activation of cellular energy sensors (i.e. adenosine monophosphate-
activated protein kinase;AMPK). Subsequently, when RNAi was used to inhibit the expression of brain-
derived leptin in adult rats this resulted in minor increases in weight gain in addition to modifying the
expression of other adipokine genes (eg. resistin). In summary, although adipokines secreted by adipose
tissue appear to the main regulator of lipostatic loop, this review shows that the fine tuning that is
required to maintain a stable bodyweight by this system might be accomplished by hypothalamic-
derived adipokines. Perturbations in this central adipokine system could lead to alterations in normal
hypothalamic function which leads to unintended weight gain.
I. OBESITYAND INDUSTRIALIZED
SOCIETIES
Obesity has reached epidemic proportions making it
one of the most common, costliest and deadliest health
conditions in industrial societies. Several hypotheses
have been put forth to account for the escalating body
mass indices (BMI) including overeating and lack of
physical activity. However, novel factors also appear to
be contributing to this modern day epidemic, including
inadequate sleep, increased environmental
concentrations of industrial endocrine disrupters,
reductions in the number of smokers, to name a few (1).
Although it remains clear that a positive energy
imbalance exists, where food intake exceeds energy
expenditure, it is worth noting that as little as a 1%
imbalance can lead to a 1Kg weight gain within one
year (2). 10Kg or more than 20 pound of weight gain
over a single decade can be caused by mere 25
excessive calories per day. Thus even the most subtle
mismatches in energy homeostasis can lead to
significant changes in body weight over a relatively
short period.
Within the last 15 years, the percentage of obese
Canadians has more than doubled, and this trend does
not appear to be subsiding (3). The proportion of
overweight and obese children is also increasing at a
staggering rate in North America (4). It has even been
suggested that economically priced super sized car seats
are now needed in the United States since nearly
300,000 children under the age of 6 exceed the current
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weight restrictions (5). For the first time in the last two
centuries, population lifetime expectancy in the US is
predicted to decrease by 0.33 to 0.75 years (6). This is
due, in part, to the increased risk of developing diabetes,
heart disease, cancer, and other co-morbidities that are
associated with carrying excess body weight (6).
Furthermore children are now being diagnosed with
“adult” diseases such as non insulin-dependent diabetes
mellitus (NIDDM). They are also at increased risk of
developing cardiovascular diseases at much earlier
ages. An estimated 10-20% of new pediatric diabetes
patients in Canada are now due to type 2 diabetes (7).
In addition to decreased life expectancy, it was
estimated that obesity directly cost Canadians over
$4.3billion in 2001 (8), a figure likely to be much higher
today.
Although diet and exercise are known to be highly
effective at inducing weight loss, few individuals
successfully maintain these reductions over the long
term, suggesting that these interventions alone are an
ineffective means to treat obesity (9). Although obesity
prevention becomes an important strategy, major
investments are needed to target the underlying
physiological mechanisms that will favor weight loss
and prevent the development of obesity. More
importantly, there is a need to identify effective
therapies that promote sustainable reductions in
bodyweight. One approach is to investigate potential
molecular mechanisms that could be used as
pharmaceutical targets to reduce bodyweight, in
addition to facilitating the maintenance of this weight
loss.
There is a large body of evidence suggesting that
obesity includes a substantial genetic component (10-
12). Early obesity studies lead to the hypothesis that
humans developed thrifty genes that offered protection
during times of famine and low availability of food
sources (13). Combined with improvements in
agriculture leading to an abundant and stable food
supply, and reduced daily physical activity (14), thrifty
genes have rendered us susceptible to gain and store the
excessive weight. It has also become evident that not
only do we need to consider what genes are present, but
how they might be differently expressed due to
imprinting and epigenetic modifications that can occur
during fetal programming (12). For example, children
born during the Dutch hunger winter of WWII are
known to have a greater incidence of obesity than others
of similar genetic background born just before or after
the war and raised in the same environment (15).
One of the major drawbacks to most weight loss
strategies is that they fail to consider how bodies defend
themselves from losing energy during periods of
starvation. An effective weight loss strategy should not
only focus on weight loss, but also on the maintenance
of a stable bodyweight afterwards. Traditional diet and
exercise, despite being effective at reducing bodyweight
acutely, often have a refractory period that favors
weight gain, restoring body mass to the pre-intervention
levels in both rodent and human models (16-18). This
suggests that bodies have a preprogrammed weight they
try to maintain by adjusting appetite and energy
expenditure within the new metabolic milieu. It is also
worth noting that experimental subjects resisted weight
gain to a certain extent when they were force fed,
suggesting that humans are equipped to maintain body
mass within a relatively narrow range (19). Although
our bodies aim to preserve a stable body mass, there
does appear to be a slight bias towards weight gain (20).
2. THE BRAIN AS AN OBESITY TARGET
TISSUE
The brain has long been recognized as a key tissue in
the development of obesity and diabetes, a target that is
sometimes overlooked in contemporary research. The
French physiologist Claude Bernard established in 1849
that the brain plays a critical role in the regulation of
blood glucose (21). By damaging the brain’s fourth
ventricle, by way of a “piqure diabetique”, he was able
to induce diabetes in dogs and others have successfully
repeated these experiments in different animal models
(22). Studies in the early part of this century revealed
that other brain regions, including the hypothalamus,
are also critical centers involved in the modulation of
peripheral glucose homeostasis (23). Further, when a
significant proportion of hypothalamic neurons are
damaged , excessive weight gain and the development
of diabetes ensued (24,25). It is now widely accepted
that there are two key populations of hypothalamic
neurons involved in bodyweight regulation; a) the
anorexigenic melanocortin neurons which express
proopiomelancortin (POMC) and reduce appetite while
elevating energy expenditure and b) the orexigenic
neurons that express neuropeptide Y (NPY) which have
the opposite effects on central energy metabolism (26).
Even slight imbalances between the outputs from these
neurons can lead to an inappropriate increase in appetite
and reduction in energy expenditure which can results
in a progressive and significant weight gain over several
years (27).
The efficiency and accuracy with which bodyweight
is regulated is incredible given the daily variations in
activity and food consumption (2,19). Hervey (1969)
points out that between the ages of 25 and 65 a women
will gain on average only 11Kg; however what is
remarkable is that she will consume over 20 tons of
food during that period (28). This suggests that our
bodies are approximately 99.7% efficient at controllingAdipokine Regulation of Obesity 179 Vol. 11 No. 2
our weight, as previously calculated by others (29).
Although it is now widely accepted that bodyweight
regulation involves a coordinated response with the
aforementioned hypothalamic neuronal populations (i.e
balance between NPY and POMC neuronal output),
many hypotheses have been put forth over the years as
to which metabolic signals are regulating the activity of
these neurons. These hypotheses include: a body
temperature-dependent indication of energy stores, a
glucostatic system, and the now widely accepted
lipostatic theory (30). In the latter model it was thought
that increase or decrease in body fat generated changes
in unknown adiposity signal(s) that could then modify
the activity of the hypothalamic pathways involved in
the control of appetite and energy expenditure (Figure
1). This model was validated following the cloning of
the anorexigenic hormone leptin from adipose tissue,
(31). It is also worth noting that several other peripheral
metabolic signals including insulin, ghrelin,
polypeptide Y3-36 (PYY3-36), cholecystokinin (CCK),
which are produced in a variety of tissues, are also
modulating the activity of the aforementioned
hypothalamic feeding centers (26,32,33).
3. THE EMERGING ENDOCRINE ROLE OF
ADIPOSE TISSUE
The cloning of the ob gene by J.M. Friedman’s
laboratory, which codes for leptin, is arguably one of the
most critical steps that initiated the ongoing study of
energy balance and bodyweight regulation (31). When
leptin is provided to leptin-deficient mice (ob/ob), or
humans, it is capable of inducing a pronounced and
sustained weight loss (34,35). Subsequent
investigations by several research groups revealed that
leptin is but one of a large family of factors secreted by
adipocytes (adipokines: (36)). These include resistin
(37); adiponectin (38), FIAF (fasting-induced adipose
factor)(39); visfatin (40); vaspin (41), and a few
unexpected candidates including nerve growth factor
(42). Application of mass spectrometry-based
proteomic techniques will likely enlarge this list of
adipocyte secreted proteins (43,44). Many of these
targets have been implicated in the regulation of
appetite, energy expenditure, insulin sensitivity, and
glycemic control, in addition to several other
functions(45,46). Thus adipokines represent a group of
obesity-related drug targets that could potentially be
harnessed to control bodyweight or treat obesity-related
illnesses such as cardiovascular disease and diabetes,
but might also impact local adipocyte metabolism via
autocrine or paracrine mechanisms.
4. LEPTIN: COMPLETING THE FAT-BRAIN
‘LIPOSTATIC’ LOOP?
It has been more than fifty years since Kennedy first
hypothesized that the brain senses fat stores in order to
control food intake, thus forming an ‘lipostatic’ system
which functions to maintain a relatively stable
bodyweight (Figure 1) (30). As described above, this
model postulated that an unknown adiposity signal was
secreted in proportion to body fat stores which acted on
the brain in order to regulate appetite and energy
expenditure in order to maintain a stable energy
balance. It took more than 4 decades in order for an
adiposity factor(s) to be identified which could be
responsible for influencing the central metabolic
pathways. The cloning of the ob gene (leptin) revived
the ‘lipostatic’ hypothesis since its expression directly
correlates with the amount of adipose tissue present, i.e.
large adipose stores are associated with increased levels
of leptin mRNA in ob/ob mice (31) and the degree of
adiposity is positively correlated with plasma leptin
concentrations (47). Given that the expression and
Figure 1: Brain adipokines and a modified lipostatic loop
It has been more than 50 years since Kennedy first proposed the
existence of a lipostatic loop in which body fat controls energy
metabolism via a hypothalamic-dependent mechanism. It is believed
that when adipose tissue mass is increased by consuming an excess of
food, leptin is then released into circulation in a proportionate manner
so it gain access to the hypothalamus in order to reduce appetite and
to promote energy expenditure. However obesity is characterized by a
resistance to these peripheral adiposity signals, so normal satiety
mechanisms fail to shut off appetite, which leads to further food
consumption and a continuous cycle of weight gain. Since brain-
derived adipokines appeared to modify key cell signaling (i.e. socs-3)
and energy sensing (i.e. AMPK) pathways implicated in central
energy metabolism, we hypothesize that centrally expressed
adipokines might form a local hypothalamic ‘tuning’ mechanism
which provides the finesse required to precisely match food intake
and energy expenditure, which is approximately 99.7% efficient.Thus
modifying the expression of hypothalamic-derived adipokines might
provide us with a means to increase the brain’s sensitivity to
peripheral metabolic signals and help restore some of the metabolic
mismatch that characterizes obesity.180 McGill Journal of Medicine 2008
release of leptin occurs in response to changes in
metabolic status (i.e. high or low energy stores augment
or reduce leptin levels respectively) (48), and that leptin
influences central metabolic pathways (49), it was
believed that leptin was the missing energy gauge that
acted on the hypothalamus in order to regulate energy
metabolism.
Defects in the lipostatic system are likely to contribute
to great weight gain. However, it is exceedingly rare to
find obese individuals who are totally devoid of leptin.
Only a handful of leptin deficient individuals have been
identified in the world (34,50), yet obesity rates are
soaring. In fact, excess bodyweight has been positively
correlated with higher circulating leptin levels in the
majority of individuals (51). This suggests that the
problem resides with how the brain is receiving and
interpreting peripheral metabolic signals, which results
in an energy imbalance and the inappropriate
stimulation of appetite. In other words the brain in an
obese patient fails to appropriately reduce appetite and
food seeking behaviors, and does not feel satiety despite
having an adequate nutrition (52). Obesity appears to be
characterized by a state of resistance to anorexigenic
signals, such as leptin. The hypothalamic insensitivity
to peripheral adiposity signals has been attributed, in
part, to modest increases in the level of signaling
molecules such as suppressor of cytokine signaling-3
(SOCS-3)(53,54). SOCS-3 binds to the intracellular
domains of leptin and insulin receptors thereby creating
a molecular traffic jam which prevents these
anorexigenic hormones from stimulating the signaling
events which lead to reductions in appetite. Therefore
very modest, but chronic, increases in hypothalamic
SOCS-3 can lead to an inappropriate increase in hunger
and hyperglycemia since the brain is unable to interpret
the messages meant to indicate that the body is
adequately nourished. Other molecular disrupters of
hypothalamic adiposity signaling events have also been
identified, including protein tyrosine phosphatase 1B. It
has also been proposed that leptin resistance occurs at
other sites, such as at the level of the blood brain barrier
(BBB). In other words, leptin fails to cross the BBB,
therefore is unable to gain access to the hypothalamus,
failing to induce any weight lowering effect (55).
Obesity appears to be characterized by a central
desensitization to peripheral adiposity signals, which
are often produced in excess.
5. COULD BRAIN-DERIVED ADIPOKINES BE
IMPACTING THE LIPOSTATIC LOOP?
Subsequent studies have shown that leptin is
expressed in a variety of tissues, most notably the
central nervous system (56). In addition to leptin (57),
the brain, pituitary gland and several brain cell line
models expresses a variety of adipokines including
adiponutrin (58), resistin (59,60) and FIAF (61). This
led to the hypothesis that brain-derived adipokines
might be serving an autocrine or paracrine role in which
they influence the regulation of appetite and impact
normal brain function (56). However a major criticism
has been that adipokine gene expression in non-adipose
tissues, in particular the brain and pituitary, is too low to
serve any biological effect (62,63). However, low
mRNA abundance does not preclude a functional role
for brain-derived adipokines (56). A notable example
includes the low level of leptin receptor mRNAdetected
in some brain areas, even though receptor protein levels
are readily detected using immunocytochemistry
(64,65). Likewise, despite the low levels of leptin
mRNA present in the human hypothalamus, it was
shown that there is a net release of leptin from the
human brain (66,67). One approach to investigate the
role of brain-derived adipokines is to specifically
silence their expression and to evaluate the
consequences on cell survival, signaling or metabolic
pathways. Although advances in molecular biology
have provided a variety of techniques that permit the
specific manipulation of target gene expression, RNA
interference (RNAi) is by far one of the most eminent.
This technique has been instrumental in the
establishment of gene function in a number of in vitro
and in vivo models, most notably in the central nervous
system (68-70).
Leptin has been implicated in a variety of brain
functions in addition to its role in the control and
regulation of appetite. One of the less prominent
features of the leptin deficient ob/ob mouse is its
reduced brain size and decreased cell number, which
could be corrected by leptin treatment (71). Subsequent
studies revealed that leptin also possesses trophic
properties that impact the hard wiring of the
hypothalamus during a critical neonatal period (72).
Hypothalamic neuronal plasticity is also affected since
leptin administration rapidly modified critical synaptic
connections implicated in the control of appetite (73).
Leptin gene expression was found to be
developmentally regulated in the rat brain and pituitary
gland (74). Leptin gene expression could also be
induced in the rat brain following traumatic brain injury
(TBI) (75). Subsequently, when RNAi was used to
specifically silence leptin gene expression in rat C6
glioblastoma cell line, a model previously validated
(76), the result was a significant 2-fold increase in cell
death as detected using either TUNEL (P < 0.005) or
ethidium homodimer-1 (P < 0.015) staining (77). This
was also consistent with anti-apoptotic pathways that
were induced by leptin treatment in the human SH-
SY5Y neuroblastoma cell line (78). Together theseAdipokine Regulation of Obesity 181 Vol. 11 No. 2
results suggest that centrally-derived leptin might be
involved in normal brain function in addition to
impacting the development of the central nervous
system (CNS), neuronal plasticity and wiring, or even
brain repair following injury.
To further investigate the novel interaction between
brain adipokines, RNAi studies on resistin and fiaf,
adipokines implicated in glucose and lipid metabolism
(37,39), were carried out in the novel N-1 hypothalamic
neuronal cell line (79). These cells were chosen since
they were derived from the embryonic mouse
hypothalamus and express a range of neuropeptides
involved in normal hypothalamic function and
metabolism. Although fiaf expression was significantly
reduced using a chemically modified small interfering
RNA (siRNA), this failed to significantly modify the
expression of other genes being analysed (60). In
marked contrast, the RNAi-mediated silencing of rstn
induced significant increases (>50%) in both fiaf and
suppressor of cytokine signaling-3 (socs-3) when N-1
cells were cultured in serum-deprived medium (60).
Likewise, resistin knockdown also reduced the ratio of
phosphorylated total adenosine monophosphate-
activated protein kinase (AMPK) (80), a novel energy
sensor implicated in the hypothalamic control of
appetite and hepatic gluconeogenesis (81-83).
Additionally the effects on fiaf and socs-3 expression,
or changes inAMPK activation, were reversed when N-
1 cells were treated with resistin, or transfected with a
resistin-expressing plasmid (60). Thus brain-derived
adipokines appear capable of regulating metabolic
signaling events (e.g. socs-3) and cellular energy
metabolism (e.g. AMPK) which might have significant
consequences on the central regulation of appetite and
energy expenditure.
Preliminary in vivo studies also confirmed that RNAi
was an effective means to acutely block the
nutritionally-mediated induction of brain-derived leptin
in the adult male rat. The intracerebroventricular (icv)
injection of a leptin-specific siRNA molecule into the
dorsal 3rd ventricle (D3V) of fasted rats, as done by
others for brain-derived neurotrophic factor (BDNF)
(84), attenuated the feeding-induced increase in
hypothalamic leptin mRNA by more than 75%
(p<0.01). This acute knockdown (24h) resulted in a
slightly greater overnight weight gain (+15%, p<0.05),
relative to rats that received the non-specific control
molecule. Similarly the continuous infusion of the
‘naked’ leptin-specific siRNA into the LV resulted in a
modest, but non-significant, reduction of leptin mRNA
(-30%) in the cortex and hypothalamus. Although no
increases in body weight were detected in the rats that
were continuously infused with the leptin-specific
siRNA, this could be due to the poor leptin knockdown
achieved. However leptin knockdown reduced the
expression of cortical resistin (-35%, p<0.05), but
paradoxically increased hypothalamic resistin by 2-fold
(p<0.05), as measured by realtime RT-PCR. Thus brain-
derived leptin appears to regulate the expression of
other centrally derived adipokines, although these
effects appear dependent on the cell-type or brain region
being analyzed. An important technical goal remains to
improve the magnitude and length of silencing achieved
under basal conditions in vivo as this greater reduction
in brain leptin expression might induce a more
pronounced phenotype.
6. BRAIN ADIPOKINES AND AN ENDOGENOUS
METABOLIC TUNING MECHANISM
These preliminary studies suggest that brain-derived
adipokines are capable of influencing brain cell survival
(e.g. leptin and C6), signaling (e.g. N-1 and socs-3), or
metabolic sensing (e.g. N-1 and AMPK). In addition
there appears to be a complex interrelationship between
centrally-derived adipokines both in vitro and in vivo.
Further studies are now needed to investigate the effects
of silencing brain-derived adipokines during critical
developmental periods, which might impact normal
brain development and function. Although adipose
tissue appears to provide the hypothalamus with the
bulk of the peripheral metabolic signals that act as
gross indicators of energy availability (26,32,85,86), it
is uncertain whether these signals alone can provide the
hypothalamus with the finesse that is required to
delicately and efficiently control bodyweight (2,28).
Perhaps the crosstalk that appears to be occurring
between centrally-derived adipokines in vivo (e.g.
leptin and resistin) could form a fine-tuning mechanism
that contributes to the precise and accurate regulation of
hypothalamic metabolic pathways via autocrine or
paracrine mechanisms (Figure 1). Thus in the context of
the lipostatic loop model, minor disruptions in
hypothalamic adipokine gene expression appear
capable of impacting the efficiency of this tightly
regulated system. Slight perturbations in this
hypothetical central adipokine system might lead to a
metabolic mismatch that increases the risk of gaining
weight or developing insulin resistance by impacting
the hypothalamic sensitivity and receptivity to
peripheral adiposity signals. As such, adjusting this
central system might allow us to improve the efficiency
of this lipostatic loop, and might even prove to be a
means to promote weight loss and help change the
bodyweight set point in obese individuals.
7. CONCLUSION
Obesity is a complex and often poorly understood
medical condition that results in unnecessary182 McGill Journal of Medicine 2008
psychological and physical suffering. Despite the
negative stereotypes associated with the obese, it is
important to recognize that deeper physiological and
genetic mechanisms might also contribute to excessive
adiposity (10-12). It is worth considering how even the
most minor of imbalances between food intake and
energy expenditure can lead to a significant and
unintended weight gain over only a few years (2,28),
and this metabolic mismatch has only been further
exacerbated in recent years by the over abundance of
highly palatable foods that are readily available on a
daily basis (14).Although we do not refute that diet and
exercise can promote weight loss, we can not ignore the
poor outcome of these programs in the long term (9,16-
18). Therefore, it is necessary to investigate other
avenues, such as the role of brain-derived adipokine in
normal body weight regulation and energy metabolism
which might prove useful to promote weight loss.
However given the complexity and redundancy of the
endogenous mechanisms that are in place to maintain
bodyweight, it seems likely that multiple approaches
will be required to effectively treat obesity.
ACKNOWLEDGMENTS
The studies in our laboratory were made possible by
financial support from the NSHRF, the IWK Health
Centre, the Atlee Endowment, UIMRF and Capital
Health. RB was the recipient of a NSHRF Graduate
Studentship. I am indebted to Dr D.D. Belsham
(University of Toronto) for the generous gift of N-1
hypothalamic neurons, and to Drs. Imran, Ur and
Wilkinson for their support. D.Wilkinson and
P.Wilkinson provided invaluable support and technical
assistance.
REFERENCES
1 Keith SW, Redden DT, et al. Putative contributors to the secular
increase in obesity: Exploring the roads less traveled. Int J Obes
2006;30:1585-1594.
2 Bray GA. Good calories, bad calories by gary taubes; new york:
Aa knopf. Obes Rev 2008
3 Katzmarzyk PT. The Canadian obesity epidemic, 1985-1998.
CMAJ. 2002;166:1039-1040.
4 Prentice AM. The emerging epidemic of obesity in developing
countries. Int J Epidemiol 2006;35:93-99.
5 Trifiletti LB, Shields W, Bishai D, McDonald E, Reynaud F,
Gielen A. Tipping the scales: Obese children and child safety
seats. Pediatrics 2006;117:1197-1202.
6 Olshansky SJ, Passaro DJ,et al. A potential decline in life
expectancy in the united states in the 21st century. N Engl J Med
2005;352:1138-1145.
7 Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes
mellitus in children and adolescents. J Pediatr 2005;146:693-
700.
8 Katzmarzyk PT, Janssen I. The economic costs associated with
physical inactivity and obesity in canada.An update. Can JAppl
Physiol 2004;29:90-115.
9 Jeffery RW, Drewnowski A, Epstein LH, Stunkard AJ, Wilson
GT, Wing RR, Hill DR. Long-term maintenance of weight loss:
Current status. Health Psychol 2000;19:5-16.
10 Friedman JM, Leibel RL. Tackling a weighty problem. Cell
1992;69:217-220.
11 Blundell JE. Appetite disturbance and the problems of
overweight. Drugs 1990;39 Suppl 3:1-19.
12 Stoger R. The thrifty epigenotype: An acquired and heritable
predisposition for obesity and diabetes? Bioessays 2008;30:156-
166.
13 Neel JV. Diabetes mellitus: A "Thrifty" Genotype rendered
detrimental by "Progress"? Am J Hum Genet 1962;14:353-362.
14 Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the
environment: Where do we go from here? Science
2003;299:853-855.
15 Ravelli GP, Stein ZA, Susser MW. Obesity in young men after
famine exposure in utero and early infancy. N Engl J Med
1976;295:349-353.
16 Kramer FM, Jeffery RW, Forster JL, Snell MK. Long-term
follow-up of behavioral treatment for obesity: Patterns of weight
regain among men and women. Int J Obes 1989;13:123-136.
17 Levin BE, Dunn-Meynell AA. Defense of body weight against
chronic caloric restriction in obesity-prone and -resistant rats.
Am J Physiol Regul Integr Comp Physiol 2000;278:R231-237.
18 Levin BE, Keesey RE. Defense of differing body weight set
points in diet-induced obese and resistant rats. Am J Physiol
1998;274:R412-419.
19 Sims EA, Horton ES. Endocrine and metabolic adaptation to
obesity and starvation. Am J Clin Nutr 1968;21:1455-1470.
20 Schwartz MW, Woods SC, Seeley RJ, Barsh GS, Baskin DG,
Leibel RL. Is the energy homeostasis system inherently biased
toward weight gain? Diabetes 2003;52:232-238.
21 Bernard C. Le￧ons de physiologie experimentale appliqu￩s ￡ l￠
medecine. Paris, Baillere et Fils, 1854.
22 Feldberg W, Pyke D, Stubbs WA. Hyperglycaemia: Imitating
claude bernard's piqure with drugs. J Auton Nerv Syst
1985;14:213-228.
23 Donhoffer C, MacLeod JJR. Studies in the nervous control of
carbohydrate metabolism. I.--the position of the centre. Proc R
Soc Lond B Biol Sci 1932;110:125-141.
24 Pizzi WJ, Barnhart JE. Effects of monosodium glutamate on
somatic development, obesity and activity in the mouse.
Pharmacol Biochem Behav 1976;5:551-557.
25 Cameron DP, Poon TK, Smith GC. Effects of monosodium
glutamate administration in the neonatal period on the diabetic
syndrome in kk mice. Diabetologia 1976;12:621-626.
26 Schwartz MW, Porte D, Jr.. Diabetes, obesity, and the brain.
Science 2005;307:375-379.
27 Lee M, Korner J. Review of physiology, clinical manifestations,
and management of hypothalamic obesity in humans. Pituitary
2008
28 Hervey GR. Regulation of energy balance. Nature
1969;222:629-631.
29 Harris RB. Role of set-point theory in regulation of body weight.
Faseb J 1990;4:3310-3318.
30 Kennedy GC. The role of depot fat in the hypothalamic control
of food intake in the rat. Proc R Soc Lond B Biol Sci
1953;140:578-596.
31 ZhangY, Proenca R, Maffei M, Barone M, Leopold L, Friedman
JM. Positional cloning of the mouse obese gene and its human
homologue. Nature 1994;372:425-432.
32 Badman MK, Flier JS. The gut and energy balance: Visceral
allies in the obesity wars. Science 2005;307:1909-1914.
33 Fry M, Hoyda TD, Ferguson AV. Making sense of it: Roles of
the sensory circumventricular organs in feeding and regulationAdipokine Regulation of Obesity 183 Vol. 11 No. 2
of energy homeostasis. Exp Biol Med (Maywood) 2007;232:14-
26.
34 Montague CT, Farooqi IS, et al. Congenital leptin deficiency is
associated with severe early-onset obesity in humans. Nature
1997;387:903-908.
35 Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT,
Rabinowitz D, Lallone RL, Burley SK, Friedman JM. Weight-
reducing effects of the plasma protein encoded by the obese
gene. Science 1995;269:543-546.
36 Trayhurn P, Bing C, Wood IS. Adipose tissue and adipokines--
energy regulation from the human perspective. J Nutr
2006;136:1935S-1939S.
37 Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR,
Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone
resistin links obesity to diabetes. Nature 2001;409:307-312.
38 Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A
novel serum protein similar to c1q, produced exclusively in
adipocytes. J Biol Chem 1995;270:26746-26749.
39 Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon
P, Gonzalez FJ, Desvergne B, Wahli W. Characterization of the
fasting-induced adipose factor fiaf, a novel peroxisome
proliferator-activated receptor target gene. J Biol Chem
2000;275:28488-28493.
40 Fukuhara A, Matsuda M, et al. Visfatin. A protein secreted by
visceral fat that mimics the effects of insulin. Science
2005;307:426-430.
41 Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A,
Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K,
Hourai S, Futami J, Watanabe E, MatsukiY, Hiramatsu R,Akagi
S, Makino H, KanwarYS. Visceral adipose tissue-derived serine
protease inhibitor:Aunique insulin-sensitizing adipocytokine in
obesity. Proc Natl Acad Sci U S A 2005;102.10610-10615.
42 Bullo M, Peeraully MR, Trayhurn P: Stimulation of ngf
expression and secretion in 3t3-l1 adipocytes by prostaglandins
pgd2, pgj2, and delta12-pgj2. Am J Physiol Endocrinol Metab
2005;289.E62-67.
43 Kratchmarova I, Kalume DE, Blagoev B, Scherer PE,
Podtelejnikov AV, Molina H, Bickel PE, Andersen JS,
Fernandez MM, Bunkenborg J, Roepstorff P, Kristiansen K,
Lodish HF, Mann M, Pandey A. A proteomic approach for
identification of secreted proteins during the differentiation of
3t3-l1 preadipocytes to adipocytes. Mol Cell Proteomics
2002;1:213-222.
44 YangYS, Song HD, Li RY, Zhou LB, Zhu ZD, Hu RM, Han ZG,
Chen JL. The gene expression profiling of human visceral
adipose tissue and its secretory functions. Biochem Biophys Res
Commun 2003;300:839-846.
45 Ahima RS. Adipose tissue as an endocrine organ. Obesity
(Silver Spring) 2006;14 Suppl 5:242S-249S.
46 Ahima RS, Lazar MA.Adipokines and the peripheral and neural
control of energy balance. Mol Endocrinol 2008;22:1023-1031.
47 Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte D, Jr..
Cerebrospinal fluid leptin levels: Relationship to plasma levels
and to adiposity in humans. Nat Med 1996;2:589-593.
48 Becker DJ, Ongemba LN, Brichard V, Henquin JC, Brichard
SM. Diet- and diabetes-induced changes of ob gene expression
in rat adipose tissue. FEBS Lett 1995;371:324-328.
49 Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P.
Recombinant mouse ob protein: Evidence for a peripheral signal
linking adiposity and central neural networks. Science
1995;269:546-549.
50 Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB,
O'Kirwan F, Whitby R, Liang L, Cohen P, Bhasin S, Krauss RM,
Veldhuis JD, WagnerAJ, DePaoliAM, McCann SM, Wong ML.
Phenotypic effects of leptin replacement on morbid obesity,
diabetes mellitus, hypogonadism, and behavior in leptin-
deficient adults. Proc NatlAcad Sci U SA2004;101:4531-4536.
51 Frederich RC, HamannA,Anderson S, Lollmann B, Lowell BB,
Flier JS. Leptin levels reflect body lipid content in mice:
Evidence for diet-induced resistance to leptin action. Nat Med
1995;1:1311-1314.
52 Jackson MB, Ahima RS. Neuroendocrine and metabolic effects
of adipocyte-derived hormones. Clin Sci (Lond) 2006;110:143-
152.
53 Bjorbaek C, El-Haschimi K, Frantz JD, Flier JS. The role of
socs-3 in leptin signaling and leptin resistance. J Biol Chem
1999;274:30059-30065.
54 Munzberg H, Myers MG, Jr.. Molecular and anatomical
determinants of central leptin resistance. Nat Neurosci
2005;8:566-570.
55 Banks WA, Farrell CL. Impaired transport of leptin across the
blood-brain barrier in obesity is acquired and reversible. Am J
Physiol Endocrinol Metab 2003;285:E10-15.
56 Wilkinson M, Brown R, Imran SA, Ur E: Adipokine gene
expression in brain and pituitary gland. Neuroendocrinology
2007;86:191-209.
57 Morash B, Li A, Murphy PR, Wilkinson M, Ur E. Leptin gene
expression in the brain and pituitary gland. Endocrinology
1999;140:5995-5998.
58 Wiesner G, Morash BA, Ur E, Wilkinson M. Food restriction
regulates adipose-specific cytokines in pituitary gland but not in
hypothalamus. J Endocrinol 2004;180:R1-6.
59 Morash BA, Wilkinson D, Ur E, Wilkinson M. Resistin
expression and regulation in mouse pituitary. FEBS Lett
2002;526:26-30.
60 Brown R, Imran SA, Belsham DD, Ur E, Wilkinson M.
Adipokine gene expression in a novel hypothalamic neuronal
cell line: Resistin-dependent regulation of fasting-induced
adipose factor and socs-3. Neuroendocrinology 2007;85:232-
241.
61 Wiesner G, Brown RE, Robertson GS, Imran SA, Ur E,
Wilkinson M. Increased expression of the adipokine genes
resistin and fasting-induced adipose factor in hypoxic/ischaemic
mouse brain. Neuroreport 2006;17:1195-1198.
62 Steppan CM, Lazar MA: The current biology of resistin. J Intern
Med 2004;255:439-447.
63 Sahu A. Leptin signaling in the hypothalamus: Emphasis on
energy homeostasis and leptin resistance. Front
Neuroendocrinol 2003;24:225-253.
64 Elmquist JK, Bjorbaek C, Ahima RS, Flier JS, Saper CB.
Distributions of leptin receptor mrna isoforms in the rat brain. J
Comp Neurol 1998;395:535-547.
65 Hakansson ML, Brown H, Ghilardi N, Skoda RC, Meister B.
Leptin receptor immunoreactivity in chemically defined target
neurons of the hypothalamus. J Neurosci 1998;18:559-572.
66 Wiesner G, Vaz M, Collier G, Seals D, Kaye D, Jennings G,
Lambert G, Wilkinson D, Esler M. Leptin is released from the
human brain: Influence of adiposity and gender. J Clin
Endocrinol Metab 1999;84:2270-2274.
67 Eikelis N, Esler M, Barton D, Dawood T, Wiesner G, Lambert G.
Reduced brain leptin in patients with major depressive disorder
and in suicide victims. Mol Psychiatry 2006;11:800-801.
68 Thakker DR, Hoyer D, Cryan JF. Interfering with the brain: Use
of rna interference for understanding the pathophysiology of
psychiatric and neurological disorders. Pharmacol Ther
2006;109:413-438.
69 Gan L, Anton KE, Masterson BA, Vincent VA, Ye S, Gonzalez-
Zulueta M. Specific interference with gene expression and gene
function mediated by long dsrna in neural cells. J Neurosci
Methods 2002;121:151-157.
70 Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello
CC. Potent and specific genetic interference by double-stranded184 McGill Journal of Medicine 2008
rna in caenorhabditis elegans. Nature 1998;391:806-811.
71 Steppan CM, Swick AG. A role for leptin in brain development.
Biochem Biophys Res Commun 1999;256:600-602.
72 Bouret SG, Draper SJ, Simerly RB. Trophic action of leptin on
hypothalamic neurons that regulate feeding. Science
2004;304:108-110.
73 Pinto S, RoseberryAG, Liu H, Diano S, Shanabrough M, Cai X,
Friedman JM, Horvath TL. Rapid rewiring of arcuate nucleus
feeding circuits by leptin. Science 2004;304:110-115.
74 Morash B, Wilkinson D, Murphy P, Ur E, Wilkinson M.
Developmental regulation of leptin gene expression in rat brain
and pituitary. Mol Cell Endocrinol 2001;185:151-159.
75 Brown R, Thompson HJ, Imran SA, Ur E, Wilkinson M.
Traumatic brain injury induces adipokine gene expression in rat
brain. Neurosci Lett 2008;432:73-78.
76 Morash B, Johnstone J, Leopold C, Li A, Murphy P, Ur E,
Wilkinson M. The regulation of leptin gene expression in the c6
glioblastoma cell line. Mol Cell Endocrinol 2000;165:97-105.
77 Brown R, Morash B, Ur E, Wilkinson M. Rnai-mediated
silencing of leptin gene expression increases cell death in c6
glioblastoma cells. Brain Res Mol Brain Res 2005;139:357-360.
78 Russo VC, Metaxas S, Kobayashi K, Harris M, Werther GA.
Antiapoptotic effects of leptin in human neuroblastoma cells.
Endocrinology 2004;145:4103-4112.
79 Belsham DD, Cai F, Cui H, Smukler SR, SalapatekAM, Shkreta
L. Generation of a phenotypic array of hypothalamic neuronal
cell models to study complex neuroendocrine disorders.
Endocrinology 2004;145:393-400.
80 Brown R, Wilkinson P, Imran SA, Ur E, Wilkinson M. Resistin
activates amp-activated protein kinase in a novel hypothalamic
neuronal cell line: Implications for central energy metabolism.
Endocrine abstracts 2008
81 Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B,
Mu J, Foufelle F, Ferre P, Birnbaum MJ, Stuck BJ, Kahn BB.
Amp-kinase regulates food intake by responding to hormonal
and nutrient signals in the hypothalamus. Nature 2004;428:569-
574.
82 McCrimmon RJ, Fan X, Cheng H, McNay E, Chan O, Shaw M,
Ding Y, Zhu W, Sherwin RS. Activation of amp-activated
protein kinase within the ventromedial hypothalamus amplifies
counterregulatory hormone responses in rats with defective
counterregulation. Diabetes 2006;55:1755-1760.
83 Kahn BB, Alquier T, Carling D, Hardie DG. Amp-activated
protein kinase: Ancient energy gauge provides clues to modern
understanding of metabolism. Cell Metab 2005;1:15-25.
84 Baker-Herman TL, Fuller DD, Bavis RW, ZabkaAG, Golder FJ,
Doperalski NJ, Johnson RA, Watters JJ, Mitchell GS. Bdnf is
necessary and sufficient for spinal respiratory plasticity
following intermittent hypoxia. Nat Neurosci 2004;7:48-55.
85 Ahima RS. Central actions of adipocyte hormones. Trends
Endocrinol Metab 2005;16:307-313.
86 Ahima RS, Qi Y, Singhal NS. Adipokines that link obesity and
diabetes to the hypothalamus. Prog Brain Res 2006;153:155-
174.
Russell Brown (M.D.C.M. 2011) has served as a senior editor for the MJM over the past year and will be
returning as a Co-Editor-In-Chief in the upcoming year. He received a B.Sc (Hons) in Biochemistry and
Molecular Biology (2003) and earned a PhD in physiology and Biophysics (2007) both from Dalhousie
University (Halifax NS). He is currently a medical student at McGill and continues to be actively involved with
investigations that focus on elucidating the various potential role(s) of brain-derived adipokines.